
Trump signs ALS and religious freedom commission bills into law
One measure renews provisions of a law on ALS therapies through fiscal year 2031; the other extends the commission’s authorisation to the end of 2028.
Review information is loading.
President Donald Trump signed two bills into law on 3 November, renewing federal measures on access to ALS therapies and extending the authorisation of the US Commission on International Religious Freedom, the White House said.
H.R. 8205 reauthorises the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031, including provisions for ALS research grants. ALS, or amyotrophic lateral sclerosis, is a neurodegenerative disease.
The law also requires officials reviewing renewals of research grants for investigational ALS drugs to request and assess enrolment, safety and any available efficacy data from the manufacturer or sponsor. The Food and Drug Administration must publish an action plan on rare neurodegenerative diseases within 18 months.
H.R. 1744 extends the religious freedom commission’s authorisation to 31 December 2028. It authorises appropriations for fiscal years 2027 and 2028 and for the final three months of 2028. An authorisation does not itself allocate funding.
Sign in to give this article a thumbs up or down.
About this discussion and AI questions
Private test discussion. Comments are readers’ views and are not yet automatically fact-checked. Editing is available for 60 seconds after posting.
Sign in with a confirmed reader account and choose a username to read comments and participate.
Sorting applies to top-level comments; replies remain oldest first. New comments and likes can change the order. Refresh for the current ranking.
Loading comments…